Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:03 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Inducing Remission in Type 1 Diabetes With Alefacept
NCT00965458 · National Institute of Allergy and Infectious Diseases (NIAID) · PHASE2 · terminated · last registry update 2017-07-06 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Manufacturer discontinued production of Amevive®: business decision.” | – | Registry record, National Institute of Allergy and Infectious Diseases (NIAID) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2018-05-11Results posted on the registry: Joshua Zeichner, Alefacept (NCT00815633)
- 2018-05-11Also stopped (terminated): Joshua Zeichner, Alefacept (NCT00815633)
- 2018-03-16Also stopped (terminated): Massachusetts General Hospital, MEDI-507 (NCT00113646)
- 2018-01-26Also stopped (terminated): The Cleveland Clinic, Alefacept (NCT01267643)
- 2017-10-02Results posted on the registry: Mayo Clinic, Alefacept (NCT00438802)
- 2017-07-27Also stopped (terminated): Emory University, Alefacept (NCT01319851)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision